- Home
- CGAU vs SLNO Comparison
CGAU vs SLNO Comparison
Compare CGAU & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | SLNO |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGAU | SLNO |
|---|---|---|
| Price | $13.38 | $50.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.17 | ★ $110.90 |
| AVG Volume (30 Days) | 824.1K | ★ 1.6M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 236.39 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $1,285,392,000.00 | $98,675,000.00 |
| Revenue This Year | $14.70 | N/A |
| Revenue Next Year | $12.63 | $155.86 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $5.41 | $41.50 |
| 52 Week High | $13.52 | $90.32 |
Technical Indicators
Market Signals| Indicator | CGAU | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 46.63 |
| Support Level | $13.08 | $47.80 |
| Resistance Level | $13.52 | $53.10 |
| Average True Range (ATR) | 0.42 | 2.35 |
| MACD | 0.05 | 0.97 |
| Stochastic Oscillator | 94.04 | 70.04 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.